Jaimee L Heffner1, Scott Coggeshall2, Chelle L Wheat2, Paul Krebs3, Laura C Feemster2,4, Deborah E Klein5, Linda Nici6,7, Hannah Johnson2,8, Steven B Zeliadt2,8. 1. Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA, USA. jheffner@fhcrc.org. 2. VA HSR&D Center of Innovation (COIN) for Veteran Centered and Value-Driven Care, Seattle, WA, USA. 3. VA San Diego Healthcare System, San Diego, CA, USA. 4. Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA. 5. Swedish Medical Group, Seattle, WA, USA. 6. Providence VA Medical Center, Providence, RI, USA. 7. Brown University, Providence, RI, USA. 8. Department of Health Services, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Implementation of effective smoking cessation interventions in lung cancer screening has been identified as a high-priority research gap, but knowledge of current practices to guide process improvement is limited due to the slow uptake of screening and dearth of data to assess cessation-related practices and outcomes under real-world conditions. OBJECTIVE: To evaluate cessation treatment receipt and 1-year post-screening cessation outcomes within the largest integrated healthcare system in the USA-the Veterans Health Administration (VHA). Design Observational study using administrative data from electronic medical records (EMR). Patients Currently smoking Veterans who received a first lung cancer screening test using low-dose CT (LDCT) between January 2014 and June 2018. Main Outcomes Tobacco treatment received within the window of 30 days before and 30 days after LDCT; 1-year quit rates based on EMR Smoking Health Factors data 6-18 months after LDCT. Key Results Of the 47,609 current smokers screened (95.3% male), 8702 (18.3%) received pharmacotherapy and/or behavioral treatment for smoking cessation; 531 (1.1%) received both. Of those receiving pharmacotherapy, only one in four received one of the most effective medications: varenicline (12.1%) or combination nicotine replacement therapy (14.3%). Overall, 5400 Veterans quit smoking-a rate of 11.3% (missing=smoking) or 13.5% (complete case analysis). Treatment receipt and cessation were associated with numerous sociodemographic, clinical, and screening-related factors. CONCLUSIONS: One-year quit rates for Veterans receiving lung cancer screening in VHA are similar to those reported in LDCT clinical trials and cohort studies (i.e., 10-17%). Only 1% of Veterans received the recommended combination of pharmacotherapy and counseling, and the most effective pharmacotherapies were not the most commonly received ones. The value of screening within VHA could be improved by addressing these treatment gaps, as well as the observed disparities in treatment receipt or cessation by race, rurality, and psychiatric conditions.
BACKGROUND: Implementation of effective smoking cessation interventions in lung cancer screening has been identified as a high-priority research gap, but knowledge of current practices to guide process improvement is limited due to the slow uptake of screening and dearth of data to assess cessation-related practices and outcomes under real-world conditions. OBJECTIVE: To evaluate cessation treatment receipt and 1-year post-screening cessation outcomes within the largest integrated healthcare system in the USA-the Veterans Health Administration (VHA). Design Observational study using administrative data from electronic medical records (EMR). Patients Currently smoking Veterans who received a first lung cancer screening test using low-dose CT (LDCT) between January 2014 and June 2018. Main Outcomes Tobacco treatment received within the window of 30 days before and 30 days after LDCT; 1-year quit rates based on EMR Smoking Health Factors data 6-18 months after LDCT. Key Results Of the 47,609 current smokers screened (95.3% male), 8702 (18.3%) received pharmacotherapy and/or behavioral treatment for smoking cessation; 531 (1.1%) received both. Of those receiving pharmacotherapy, only one in four received one of the most effective medications: varenicline (12.1%) or combination nicotine replacement therapy (14.3%). Overall, 5400 Veterans quit smoking-a rate of 11.3% (missing=smoking) or 13.5% (complete case analysis). Treatment receipt and cessation were associated with numerous sociodemographic, clinical, and screening-related factors. CONCLUSIONS: One-year quit rates for Veterans receiving lung cancer screening in VHA are similar to those reported in LDCT clinical trials and cohort studies (i.e., 10-17%). Only 1% of Veterans received the recommended combination of pharmacotherapy and counseling, and the most effective pharmacotherapies were not the most commonly received ones. The value of screening within VHA could be improved by addressing these treatment gaps, as well as the observed disparities in treatment receipt or cessation by race, rurality, and psychiatric conditions.
Authors: Edwin S Wong; Virginia Wang; Chuan-Fen Liu; Paul L Hebert; Matthew L Maciejewski Journal: Med Care Res Rev Date: 2015-11-20 Impact factor: 3.929
Authors: Philip H Smith; Biruktawit Assefa; Simranpreet Kainth; Kaliris Y Salas-Ramirez; Sherry A McKee; Gary A Giovino Journal: Nicotine Tob Res Date: 2020-03-16 Impact factor: 4.244
Authors: Linda S Kinsinger; Charles Anderson; Jane Kim; Martha Larson; Stephanie H Chan; Heather A King; Kathryn L Rice; Christopher G Slatore; Nichole T Tanner; Kathleen Pittman; Robert J Monte; Rebecca B McNeil; Janet M Grubber; Michael J Kelley; Dawn Provenzale; Santanu K Datta; Nina S Sperber; Lottie K Barnes; David H Abbott; Kellie J Sims; Richard L Whitley; R Ryanne Wu; George L Jackson Journal: JAMA Intern Med Date: 2017-03-01 Impact factor: 21.873
Authors: Brian C Martinson; A Lauren Crain; Nancy E Sherwood; Marcia G Hayes; Nicolaas P Pronk; Patrick J O'Connor Journal: J Phys Act Health Date: 2010-01
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Peter J Mazzone; Gerard A Silvestri; Sheena Patel; Jeffrey P Kanne; Linda S Kinsinger; Renda Soylemez Wiener; Guy Soo Hoo; Frank C Detterbeck Journal: Chest Date: 2018-02-17 Impact factor: 9.410
Authors: Patrick S Calhoun; Sarah M Wilson; Jeffrey S Hertzberg; Angela C Kirby; Scott D McDonald; Paul A Dennis; Lori A Bastian; Eric A Dedert; Jean C Beckham Journal: J Gen Intern Med Date: 2017-08-14 Impact factor: 6.473
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321